DV
Dividend Vision

RNTX — Rein Therapeutics Inc

Rein Therapeutics Inc (RNTX)

Total return is -99.6% over the past 9.1 years, 369.7 points behind SPY at 270.1%. Its deepest 1-year drawdown was 62.0%.

Rein Therapeutics Inc. is a biopharmaceutical company developing medicines for orphan pulmonary and fibrosis indications, with its lead candidate LTI-03 currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis and additional pipeline programs targeting cystic fibrosis and systemic fibrosis. The company does not currently distribute dividends. Rein Therapeutics appeals primarily to investors seeking exposure to early-stage biopharmaceutical development rather than income generation.

RNTX key facts

Asset type
Stock
Asset class
Equity
Inception date
06/29/2017
Last close
$0.81
Market cap
$76,540,328
Average volume
213500.0
Beta
1.348
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.98